Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs IDEXX Laboratories, Inc. — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.51 (market cap $746.48M), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 54.2× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FEPI | IDXX | |
|---|---|---|
Market Cap | $746.48M | $40.43B |
Volume | 334,337 | 692,164 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $766.68 |
52-Week Low | $37.98 | $504.70 |
Typical Hold Time | 56 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.18, down 0.94% with a bullish technical signal from moving averages. The ETF employs a covered call strategy on AI and mega-cap tech stocks, generating substantial weekly dividends averaging $0.20-0.21 per share. Technical indicators show support at $43 and resistance at $44, with RSI suggesting potential overbought conditions. Recent news highlights FEPI's 25% yield but notes underperformance versus peers in total returns.
The outlook remains income-focused with high yield appeal, though capped upside and concentrated tech exposure present risks. Elevated volatility in AI sectors could impact distributions, while competitive covered call ETFs offer alternatives. Investors should weigh income stability against total return potential and sector concentration risks in the current market environment.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
